UPDATE 1-Cardiovascular drug developer Kardigan files for US IPO

Adds details throughout

May 26 (Reuters) - Cardiovascular drug developer Kardigan on Tuesday filed for an initial public offering in the United States.

A rebound in biotech IPO issuance signals improving risk appetite in equity markets, as investors return to healthcare companies with advanced-stage drug pipelines and clearer paths toward commercialization.

Kardigan is a U.S.-based clinical-stage biotechnology company developing precision medicines for cardiovascular diseases. The company is advancing three late-stage experimental therapies.

Kardigan will list on the Nasdaq Global Market under the ticker symbol "KARD".

J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are the underwriters for the offering.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.